Saturday, 21 April 2018

Lupin inks research pact with CSIR-NCL, DST

09 March 2018 | News

Through this research collaboration, CSIR-NCL and Lupin would together work towards the development of a novel continuous purification process for manufacturing mAb therapeutics.

Image credit- diaglobal.org

Image credit- diaglobal.org

Lupin has entered into an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology, (DST, Delhi) for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic (mAb).

With an increasing demand for biosimilar therapeutics and an ever-increasing pressure for manufacturing cost reduction with quality maintenance, the biopharmaceutical industry is showing keen interest in the development of continuous manufacturing processes.

Through this research collaboration, CSIR-NCL and Lupin would together work towards the development of a novel continuous purification process for manufacturing mAb therapeutics. Biopharmaceuticals, biologics and monoclonal antibodies are the next wave of discovery and innovation in new pharmaceuticals.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Can access to vaccines reduce the threat of antibiotic resistance?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls